Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

dc.citation.volumeNumber6
dc.contributor.authorKüçük, C.en_US
dc.contributor.authorJiang, B.en_US
dc.contributor.authorHu X.en_US
dc.contributor.authorZhang W.en_US
dc.contributor.authorChan J.K.C.en_US
dc.contributor.authorXiao W.en_US
dc.contributor.authorLack, N.en_US
dc.contributor.authorAlkan, C.en_US
dc.contributor.authorWilliams J.C.en_US
dc.contributor.authorAvery, K.N.en_US
dc.contributor.authorKavak P.en_US
dc.contributor.authorScuto, A.en_US
dc.contributor.authorSen, E.en_US
dc.contributor.authorGaulard P.en_US
dc.contributor.authorStaudt L.en_US
dc.contributor.authorIqbal J.en_US
dc.contributor.authorZhang W.en_US
dc.contributor.authorCornish, A.en_US
dc.contributor.authorGong Q.en_US
dc.contributor.authorYang Q.en_US
dc.contributor.authorSun H.en_US
dc.contributor.authorD'Amore F.en_US
dc.contributor.authorLeppä, S.en_US
dc.contributor.authorLiu W.en_US
dc.contributor.authorFu, K.en_US
dc.contributor.authorDe Leval L.en_US
dc.contributor.authorMcKeithan, T.en_US
dc.contributor.authorChan W.C.en_US
dc.date.accessioned2016-02-08T10:19:49Z
dc.date.available2016-02-08T10:19:49Z
dc.date.issued2015
dc.departmentDepartment of Computer Engineering
dc.description.abstractLymphomas arising from NK or γδ-T cells are very aggressive diseases and little is known regarding their pathogenesis. Here we report frequent activating mutations of STAT3 and STAT5B in NK/T-cell lymphomas (n=51), γδ-T-cell lymphomas (n=43) and their cell lines (n=9) through next generation and/or Sanger sequencing. STAT5B N642H is particularly frequent in all forms of γδ-T-cell lymphomas. STAT3 and STAT5B mutations are associated with increased phosphorylated protein and a growth advantage to transduced cell lines or normal NK cells. Growth-promoting activity of the mutants can be partially inhibited by a JAK1/2 inhibitor. Molecular modelling and surface plasmon resonance measurements of the N642H mutant indicate a marked increase in binding affinity of the phosphotyrosine-Y699 with the mutant histidine. This is associated with the prolonged persistence of the mutant phosphoSTAT5B and marked increase of binding to target sites. Our findings suggest that JAK-STAT pathway inhibition may represent a therapeutic strategy. © 2015 Macmillan Publishers Limited. All rights reserved.
dc.identifier.doi10.1038/ncomms7025
dc.identifier.issn20411723
dc.identifier.urihttp://hdl.handle.net/11693/23825
dc.language.isoEnglish
dc.publisherNature Publishing Group
dc.relation.isversionofhttp://dx.doi.org/10.1038/ncomms7025
dc.source.titleNature Communications
dc.subjecthistidine
dc.subjectJanus kinase 2 inhibitor
dc.subjectJanus kinase inhibitor
dc.subjectmutant protein
dc.subjectphosphotyrosine
dc.subjectSTAT5b protein
dc.subjectdisease treatment
dc.subjectinhibition
dc.subjectmolecular analysis
dc.subjectmutation
dc.subjectparthenogenesis
dc.subjectprotein
dc.subjecttumor
dc.subjectArticle
dc.subjectbinding affinity
dc.subjectbinding site
dc.subjectcancer growth
dc.subjectcontrolled study
dc.subjectgamma delta T lymphocyte
dc.subjectgene mutation
dc.subjecthuman
dc.subjecthuman cell
dc.subjectlymphoma cell line
dc.subjectmeasurement
dc.subjectmolecular model
dc.subjectmutator gene
dc.subjectnatural killer cell
dc.subjectNK T cell lymphoma
dc.subjectprotein phosphorylation
dc.subjectSTAT3 gene
dc.subjectSTAT5B gene
dc.subjectsurface plasmon resonance
dc.subjectT cell lymphoma
dc.titleActivating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
Description:
Full printable version